Search Results Within Category "Heart and Vascular"
Suggestions within category "Heart and Vascular"
The Radial vs. State-Of-The-Art FEmoral Access for Bleeding and Access SIte Complication Reduction in Cardiac CaTHeterization (REBIRTH) Trial
The primary study objective is to evaluate whether radial access for cardiac catheterization of patients reduces vascular access complications and bleeding occurring within 72 h of the procedure or by hospital discharge, when compared with state-of-the-art femoral access. Patients randomized to femoral access will be further randomized to use of a micropuncture (21 gauge) vs. standard (18 gauge) needle.
Michelle Butcher - mbutche1@hfhs.org
• Age greater than 18 years
• Patients undergoing cardiac catheterization
• Has provided informed consent and agrees to participate
• Patients must be equally eligible to undergo cardiac catheterization via radial or femoral access
• Patients arriving for emergency heart attack
• Patients undergoing only planned right heart catheterization, with no plan for concurrent left heart catheterization
• Valvular heart disease requiring valve surgery within 30 days after the index procedure
• Hemodialysis access (arteriovenous fistula or graft) in the arm to be used for PCI in case of assignment to radial approach (the opposite arm may be used for radial access if a dialysis graft is present in one)
• Peripheral arterial disease prohibiting vascular access
A Randomized Comparison of Cleerly Coronary Artery Disease Stage-Based Care Versus Risk Factor-Based Care for Primary Prevention of Cardiovascular Events (TRANSFORM)
This research study is testing whether using heart artery imaging and personalized treatment plans can better prevent heart attacks and other heart-related problems in people at higher risk for heart disease, even if they do not have symptoms. The study includes adults with diabetes, prediabetes, or metabolic syndrome and compares this approach to standard care based only on traditional risk factors.
Jodi Carter - GeneralCardiologyResearch@hfhs.org
• Men over the age of 55, women over the age of 65
• Must have type 2 diabetes, prediabetes, or metabolic syndrome
• History of established cardiovascular disease
• Decreased kidney function
• Allergy to contrast
• LDL of <70 mg/dL
AGENT DCB STANCE: AGENT Drug-Coated Balloon for STent AvoidANCE in PCI for De Novo Coronary Artery Disease
The AGENT DCB STANCE study will compare the AGENT Paclitaxel Coated Balloon Catheter to standard of care treatment with drug-eluting stents and/or balloon medical procedure to open blocked or narrowed blood vessels.
Melanee Schimmel, BSN, RN - mschimm2@hfhs.org
• Must be at least 18 yrs of age
• Understands and the willingness to comply with all study required follow-up evaluation
• Women of child-bearing potential must agree to use a reliable method of contraception for 1 year.
• Other serious medical illness that may reduce life expectancy to less than 1 year.
• Serious problem with substances (alcohol, cocaine, heroin, etc.)
• Currently participating in another experimental drug/device study that has not met the outcome the study is measuring
• Is pregnant and nursing
• Has had a non-surgical procedure used to open narrowed or blocked coronary arteries with a balloon or stent
• Been diagnosed with severe heart failure within the past 6 months
• Known allergy to paclitaxel or other parts of the medical devices that are used.
• Severe renal failure
THE MAGENTA ELEVATE HIGH-RISK PCI PIVOTAL TRIAL PROTOCOL (ELEVATE III)
For patients having a procedure to open severe blockages in the heart's arteries. Due to your severe blockages and weakened heart function, you may be at higher risk of having a drop in blood flow. THE MAGENTA ELEVATE device heart pump device is used during the procedure. This device is intended to prevent drops in blood flow during the procedure. It does this by assisting the heart in pumping blood through the body.
MICHELLE BUTCHER - MBUTCHE1@HFHS.ORG